Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Diabetic macular edema (DME) is a major vision-threatening complication of diabetes caused by fluid accumulation in the macula following disruption of the inner blood-retinal barrier. A 2026 systematic review and meta-analysis by Marques-Couto et al., covering 63 studies and 20,074 patients, estimated DME prevalence among people with type 1 diabetes at 11.1% (95% CI: 7.9–14.3%), with very low evidence certainty and substantial heterogeneity. According to the diabetic macular edema epidemiology forecast by Expert Market Research, DME remains a substantial healthcare burden due to progressive visual impairment, diabetes-related comorbidities, repeated intravitreal injections, treatment discontinuation, specialist capacity constraints and associated economic costs.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Diabetic Macular Edema (DME) – Number of Cases by Year

Read more about this report - Request a Free Sample

Diabetic Macular Edema (DME) Epidemiology Forecast Report Coverage

Expert Market Research's “Diabetic Macular Edema (DME) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Diabetic Macular Edema (DME). It projects the future incidence and prevalence rates of Diabetic Macular Edema (DME) cases across various populations. The study covers age, gender, and type as major determinants of the Diabetic Macular Edema (DME) population. The report highlights patterns in the prevalence of Diabetic Macular Edema (DME) overtime and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Diabetic Macular Edema (DME) in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Diabetic Macular Edema (DME) Understanding: Disease Overview

Diabetic macular edema (DME) remains a major vision-threatening microvascular complication of diabetes mellitus characterized by accumulation of extracellular and intracellular fluid within the macula following disruption of the inner blood-retinal barrier. Hyperglycemia-induced oxidative stress, pericyte dysfunction, endothelial injury, inflammatory signalling, leukostasis and vascular endothelial growth factor (VEGF) overexpression contribute to vascular permeability and macular thickening. DME can occur in both type 1 and type 2 diabetes and may develop at different stages of diabetic retinopathy. Contemporary clinical assessment increasingly distinguishes center-involving DME (CI-DME) from non-center-involving disease because involvement of the foveal center has major implications for visual function and treatment selection.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

Patients with long diabetes duration, poor glycemic control, hypertension, nephropathy, dyslipidemia, anemia, diabetic retinopathy and previous DME,

Key Diagnostic Method

Optical coherence tomography (OCT)

Major Risk Factor

Longer diabetes duration and inadequate glycemic control

Major gap in the market

Frequent injection requirements, treatment non-adherence, variable anti-VEGF response, persistent DME, incomplete visual recovery, limited predictive biomarkers and high treatment costs

Diabetic Macular Edema (DME) Epidemiology Perspective

The Diabetic Macular Edema (DME) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Diabetic Macular Edema (DME) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Diabetic Macular Edema (DME) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Marques-Couto et al., the 2026 systematic review and meta-analysis estimated pooled DME prevalence at 11.1% among people with type 1 diabetes, based on 20,074 patients across 63 studies, although the evidence had very low certainty and substantial heterogeneity.

Gender-Specific Cases of the Disease

Contemporary evidence does not demonstrate a uniform strong sex predominance. The 2026 U.S. meta-analysis reported higher age-standardized DME prevalence in males than females, but sex differences should be interpreted in conjunction with diabetes type, duration, treatment exposure and healthcare access rather than as an independent biological determinant.

Age-Specific Cases of the Disease

DME can occur across adulthood, but risk generally increases with longer diabetes duration, which correlates with older age in many clinical populations. The 2026 type 1 diabetes meta-analysis found diabetes duration to be a significant predictor of DME prevalence, with each additional year of diabetes associated with an average increase of 1.2 percentage points in prevalence in its meta-regression.

Ethnicity-Wise Cases of the Disease

Contemporary U.S. evidence demonstrates pronounced disparities. The 2026 meta-analysis found DME prevalence more than four times higher among Black individuals than White individuals and approximately 3.7 times higher among Hispanic individuals than White individuals after age standardization. These differences may reflect diabetes burden, disease control, social determinants, healthcare access and treatment disparities rather than ethnicity itself.

Mortality and Survival Analysis of the Disease

DME is primarily a vision-threatening complication of diabetes rather than a direct cause of death. However, diabetic retinopathy and clinically significant macular edema have been associated with increased all-cause mortality, with studies reporting a 1.55-fold to 2.37-fold higher mortality risk.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Center-Involving Diabetic Macular Edema (CI-DME)

CI-DME affects the central subfield of the macula and is particularly important because foveal involvement can cause clinically significant visual impairment. OCT is central to diagnosis and quantitative monitoring. Anti-VEGF therapy is generally the principal pharmacological treatment for eyes with center-involving edema and visual impairment.

Non-Center-Involving DME

Non-center-involving DME produces retinal edema outside the central subfield. Depending on severity and visual impact, observation, systemic metabolic optimization and focal/grid laser can be considered. Contemporary imaging allows more precise differentiation between center-involving and non-center-involving disease.

Mild / Early DME

Early DME may have limited visual consequences and can occur alongside non-proliferative diabetic retinopathy. Risk-factor modification, appropriate retinal surveillance and prompt treatment when edema threatens central vision are important to prevent progression.

Persistent / Refractory DME

Persistent DME describes edema that remains despite adequate anti-VEGF exposure or recurs repeatedly. It is one of the most important treatment gaps because fluid may persist despite anatomical improvement and vision may remain suboptimal. Contemporary literature increasingly supports switching mechanisms or incorporating corticosteroid therapy in selected cases.

Diabetic Macular Edema (DME) – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Diabetic Macular Edema (DME) Epidemiology

The Diabetic Macular Edema (DME) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

A 2026 U.S. meta-analysis estimated an age-standardized DME prevalence of 317 per 100,000 population, with markedly higher prevalence among Black and Hispanic populations. Because the underlying prevalence datasets were collected through 2022, the figure is not represented as a current 2023–2026 observation.

Germany

Contemporary German real-world evidence demonstrates a substantial treatment burden. The 2025 university-hospital study characterized 176 treated eyes among 114 patients and found that 71.59% had already received previous DME treatment; patients required an average of 3.91 intravitreal injections per eye during the study period.

France

France represents a mature European retinal-care market with established access to anti-VEGF therapy and increasing emphasis on treatment durability. French centres contributed to the 2026 RHONE-X four-year faricimab study, which demonstrated sustained visual and anatomical improvement and approximately 80% of patients reaching dosing intervals of at least 12 weeks.

Italy

Italy represents an important European DME market with increasing economic interest in extended-duration anti-VEGF therapy. A 2026 Italian cost-minimization analysis evaluated aflibercept 8 mg against other anti-VEGF options and specifically identified high treatment burden, healthcare-resource utilization and patient adherence as important issues in DME care.

Spain

A 2025 Spanish real-world study evaluated 105 eyes from 79 patients treated with faricimab between January 2024 and January 2025, including treatment-naïve and previously treated eyes. The study demonstrated the practical use of faricimab in contemporary Spanish retinal practice and supports its role in both initial and switch populations.

United Kingdom

A 2026 Liverpool real-world study evaluated centre-involving DME treated with faricimab and reported clinically meaningful one-year outcomes while identifying evidence of undertreatment in routine practice. The 2025 FARWIDE-DMO study also provides contemporary UK evidence on real-world faricimab use and treatment patterns.

Japan

A 2026 Japanese real-world study of 380 treatment-naïve patients with centre-involving DME found that 14.5% discontinued anti-VEGF treatment themselves. Younger age and poorer baseline visual acuity were associated with discontinuation, demonstrating that adherence is a significant determinant of real-world outcomes.

India

India represents a major growth market for DME because of its large diabetes population and expanding retinal-care infrastructure. A 2026 randomized controlled study conducted in India between January 2024 and June 2025 found comparable 48-week efficacy between faricimab and aflibercept in treatment-naïve patients, while faricimab provided significantly longer dosing intervals of 12.86 versus 9.47 weeks.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

According to contemporary 2023–2026 evidence, significant gaps remain in the epidemiological characterization, early detection, treatment adherence and long-term visual management of diabetic macular edema. The principal challenge is that DME prevalence varies substantially according to diabetes type, disease duration, retinopathy severity and the diagnostic modality used. The 2026 type 1 diabetes meta-analysis estimated pooled prevalence at 11.1%, but very high heterogeneity and very low certainty of evidence demonstrate the limitations of applying a single prevalence estimate across all diabetic populations. A major opportunity therefore exists in systematic retinal screening and earlier OCT detection. DME can produce clinically important macular changes before patients recognize substantial visual deterioration. Integration of retinal imaging into diabetes-management pathways and more rapid referral of patients with macular involvement can potentially shorten the interval between structural disease and treatment.

Diabetic Macular Edema (DME): Treatment Overview

The management of diabetic macular edema primarily focuses on preventing or reversing retinal fluid accumulation, preserving or improving visual acuity, limiting structural retinal damage, reducing progression of diabetic retinopathy and minimizing the long-term burden of repeated treatment. Contemporary management combines ophthalmic treatment with optimization of systemic diabetes and cardiovascular risk factors. The current therapeutic framework is increasingly based on the distinction between center-involving and non-center-involving DME, baseline visual acuity, previous treatment exposure, persistent retinal fluid, diabetic retinopathy severity and patient-specific treatment burden. Systemic metabolic control remains fundamental. Glycemic control, blood-pressure management, lipid management and treatment of renal disease are important components of DME prevention and long-term retinal protection.

Key Questions Answered

  • What is the current and projected burden of Diabetic Macular Edema (DME) across the 8 major markets?
  • Which countries across the 8 major markets account for the highest Diabetic Macular Edema (DME) patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of Diabetic Macular Edema (DME) across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Diabetic Macular Edema (DME) across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Diabetic Macular Edema (DME) across the 8 major markets?
  • How do major comorbidities and risk factors influence Diabetic Macular Edema (DME) epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Diabetic Macular Edema (DME) across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Diabetic Macular Edema (DME) landscape across the 8 major markets?
  • Which therapeutic areas linked to Diabetic Macular Edema (DME) are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the Diabetic Macular Edema (DME) epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on Diabetic Macular Edema (DME) epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Diabetic Macular Edema (DME) across the 8 major markets?

Scope of the Diabetic Macular Edema (DME) Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Diabetic Macular Edema (DME) based on several factors.
  • Diabetic Macular Edema (DME) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Diabetic Macular Edema (DME) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Diabetic Ulcer Treatment Market

Diabetes Drugs Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us